Coronary collaterals in patients with ST-elevation myocardial infarction presenting late after symptom onset.


Journal

Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 14 01 2020
accepted: 02 03 2020
pubmed: 15 3 2020
medline: 24 7 2021
entrez: 15 3 2020
Statut: ppublish

Résumé

The role of coronary collaterals in ST-elevation myocardial infarction (STEMI) remains controversial. So far, studies examining the effect of collaterals on outcome mainly focused on patients presenting early after symptom onset. We sought to investigate the prognostic influence of coronary collateralization in patients presenting with prolonged ischemia late after symptom onset. The study is a subanalysis of a randomized trial addressing thrombus aspiration in STEMI patients presenting between 12 and 48 h after symptom onset with a follow-up period of a minimum of 4 years. A total of 95 patients with a Thrombolysis In Myocardial Infarction (TIMI) flow grade 0 or 1 prior to percutaneous coronary intervention (PCI) were included in the analysis. Of these, 62 patients (65%) had none or poor coronary collateralization according to the Rentrop classification (Rentrop grade 0 or 1) compared to 33 (35%) with well-developed collateralization (Rentrop grade 2 or 3). In comparison, patients with well-developed collateralization had a smaller area of microvascular obstruction (2.1 ± 3.8 vs. 4.5 ± 4.9% of left ventriclular mass (%LV), p = 0.03) and infarct size (27.9 ± 11.7 vs. 34.8 ± 17.2% LV, p = 0.047) on magnetic resonance imaging. Further, mortality at 4-years follow-up was lower (6% Rentrop grade 2 or 3 vs. 25% Rentrop grade 0 or 1, p = 0.02). Poor collateralization was an independent predictor of long-term mortality on multivariate Cox regression analyses in addition to cardiogenic shock and unsuccessful PCI during the index procedure. Sufficient coronary collateralization has a positive impact on microvascular obstruction, infarct size and long-term mortality in STEMI patients presenting between 12 and 48 h after symptom onset.

Sections du résumé

BACKGROUND BACKGROUND
The role of coronary collaterals in ST-elevation myocardial infarction (STEMI) remains controversial. So far, studies examining the effect of collaterals on outcome mainly focused on patients presenting early after symptom onset. We sought to investigate the prognostic influence of coronary collateralization in patients presenting with prolonged ischemia late after symptom onset.
METHODS AND RESULTS RESULTS
The study is a subanalysis of a randomized trial addressing thrombus aspiration in STEMI patients presenting between 12 and 48 h after symptom onset with a follow-up period of a minimum of 4 years. A total of 95 patients with a Thrombolysis In Myocardial Infarction (TIMI) flow grade 0 or 1 prior to percutaneous coronary intervention (PCI) were included in the analysis. Of these, 62 patients (65%) had none or poor coronary collateralization according to the Rentrop classification (Rentrop grade 0 or 1) compared to 33 (35%) with well-developed collateralization (Rentrop grade 2 or 3). In comparison, patients with well-developed collateralization had a smaller area of microvascular obstruction (2.1 ± 3.8 vs. 4.5 ± 4.9% of left ventriclular mass (%LV), p = 0.03) and infarct size (27.9 ± 11.7 vs. 34.8 ± 17.2% LV, p = 0.047) on magnetic resonance imaging. Further, mortality at 4-years follow-up was lower (6% Rentrop grade 2 or 3 vs. 25% Rentrop grade 0 or 1, p = 0.02). Poor collateralization was an independent predictor of long-term mortality on multivariate Cox regression analyses in addition to cardiogenic shock and unsuccessful PCI during the index procedure.
CONCLUSION CONCLUSIONS
Sufficient coronary collateralization has a positive impact on microvascular obstruction, infarct size and long-term mortality in STEMI patients presenting between 12 and 48 h after symptom onset.

Identifiants

pubmed: 32170359
doi: 10.1007/s00392-020-01625-w
pii: 10.1007/s00392-020-01625-w
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1307-1315

Auteurs

Anne Freund (A)

Heart Center Leipzig, Department of Internal Medicine/Cardiology, University of Leipzig, Strümpellstr. 39, 04289, Leipzig, Germany. anne.freund@medizin.uni-leipzig.de.
German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany. anne.freund@medizin.uni-leipzig.de.
Leipzig Heart Institute, Leipzig, Germany. anne.freund@medizin.uni-leipzig.de.

Thomas Stiermaier (T)

German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany.
University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.

Suzanne de Waha-Thiele (S)

German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany.
University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.

Ingo Eitel (I)

German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany.
University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.

Sandra Schock (S)

Heart Center Leipzig, Department of Internal Medicine/Cardiology, University of Leipzig, Strümpellstr. 39, 04289, Leipzig, Germany.

Philipp Lurz (P)

Heart Center Leipzig, Department of Internal Medicine/Cardiology, University of Leipzig, Strümpellstr. 39, 04289, Leipzig, Germany.

Holger Thiele (H)

Heart Center Leipzig, Department of Internal Medicine/Cardiology, University of Leipzig, Strümpellstr. 39, 04289, Leipzig, Germany.
Leipzig Heart Institute, Leipzig, Germany.

Steffen Desch (S)

Heart Center Leipzig, Department of Internal Medicine/Cardiology, University of Leipzig, Strümpellstr. 39, 04289, Leipzig, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany.
Leipzig Heart Institute, Leipzig, Germany.
University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH